SCHEMBL4403555

SCHEMBL4403555

Cc1ccc(N2CCN(CC(N)=O)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
CA7 P43166 2/20 0.56
GFER P55789 1/20 0.56
CA9 Q16790 1/20 0.54
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ATM Q13315 1/20 0.51
AKR1C3 P42330 1/20 0.50
GAA P10253 1/20 0.49
PKM P14618 1/20 0.49
DRD4 P21917 1/20 0.49
TSHR P16473 1/20 0.49
HTT P42858 2/20 0.49
MAPT P10636 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
ALDH1A1 P00352 2/20 0.48
SLC27A1 Q6PCB7 1/20 0.48
LMNA P02545 1/20 0.48
GLA P06280 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26373091 0.85 S1PR1 (0.61) CA1CA2CA7GFERCA9
SCHEMBL6698451 0.85 MAPT (0.59) GFERMEN1KMT2AGAAHTT
SCHEMBL10963122 0.85 ME2 (0.58) GFERMEN1KMT2AGAAPKM
SCHEMBL27615959 0.84 KMT2A (0.56) MEN1KMT2AHTTMAPTNPSR1
SCHEMBL28201211 0.83 MEN1 (0.51) CA1CA2CA7MEN1KMT2A
SCHEMBL6698448 0.83 ALDH1A1 (0.61) GFERMEN1KMT2AHTTMAPT
SCHEMBL4400390 0.83 SMN1; SMN2 (0.66) CA1CA2CA7GFERCA9
SCHEMBL4179918 0.83 GAA (0.60) CA1CA2CA7MEN1KMT2A
SCHEMBL4172010 0.83 MAPT (0.68) GFERMEN1KMT2AATMPKM
SCHEMBL4393525 0.83 MEN1 (0.64) GFERMEN1KMT2AGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 CA1 4150/4885CA2 3039/4885CA7 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.